5月26日，先健科技公告显示，其研发的主动脉弓支架系统获国家药监局正式注册批准。该产品是国内首款使用开窗技术进行主动脉弓部分支重建的覆膜支架系统，适用于Stanford B型主动脉夹层患者的治疗。该解决方案创伤更小、操作更简单，可精准维持左锁骨下动脉血流灌注。先健科技拥有自主知识产权，此产品丰富了其在外周血管介入领域的产品组合。受此消息影响，公司股价早盘上涨7.01%，报1.68港元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.